Skip to content
Blackberry Empire – Lifestyle
Author:
BIOMARIN PHARMACEUTICAL INC.
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
July 27, 2026
U.S. Food and Drug Administration Accepts BioMarin’s Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
July 13, 2026
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
June 16, 2026
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
May 21, 2026
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
May 18, 2026
BioMarin Reports First Quarter 2026 Financial and Operating Results
May 5, 2026
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society’s 2026 Annual Meeting
May 4, 2026
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society’s 2026 Annual Meeting
May 4, 2026
BioMarin Completes Acquisition of Amicus Therapeutics
April 27, 2026
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
April 27, 2026
1
2
Next Page
→